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Aims To evaluate the safety proﬁle and efﬁcacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-
segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to
4 years follow-up.
Methods
and results
Eighty-six patients with STEMI who had successfully undergone percutaneous coronary intervention (PCI) were ran-
domized to receive intracoronary injection of BMMNC (n ¼ 41) or saline (n ¼ 45). Left ventricular ejection fraction,
as evaluated by UCG, was markedly improved at 6 months (0.484+0.5 vs. 0.457+0.6, P ¼ 0.001), 1 year
(0.482+0.7 vs. 0.446+0.6, P , 0.001), and 4 years (0.505+0.8 vs. 0.464+0.8, P , 0.001) after BMMNC trans-
plant when compared with control group. However, the current cell therapy did not improve the myocardial viability
of the infarcted area as assessed by single-photon emission computed tomography analysis at 4 years post-transplant
(0.263+0.007 in BMMNC group vs. 0.281+0.008 in control group, P ¼ 0.10). During the follow-up period, one
control group case (2.2%) of in-stent restenosis was conﬁrmed by coronary angiography and underwent repeat
PCI. Also during follow-up, one death (2.2%) occurred in the control group, and one patient (2.4%) in the
BMMNC group had transient acute heart failure.
Conclusion This study indicates that intracoronary delivery of autologous BMMNC is safe and feasible for STEMI patients who
have undergone PCI, and can lead to long-term improvement in myocardial function.
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Acute myocardial infarction (AMI) resulting from atherosclerotic
obstruction or arterial narrowing remains the leading cause of
morbidity and mortality worldwide.
1,2 Current therapies for AMI
such as percutaneous coronary intervention (PCI) can localize
the AMI-affected area, normalize coronary perfusion, and enable
viable ischaemic tissue to recover, thus limiting further necrosis.
However, many patients develop left ventricular (LV) remodelling
and progressive heart failure after AMI. The restoration of cardiac
function in such situations remains a major challenge.
Stem cells are capable of the important properties of self-
renewal and differentiation plasticity.
3,4 Human autologous bone
marrow mononuclear cells (BMMNC) contain CD34
þ haemato-
poietic and CD34
2 mesenchymal stem cells.
5 Both of these cell
types may contribute to heart muscle repair in AMI. In recent
years, a variety of clinical trials have explored the hypothesis that
BMMNC transplantation may enhance the recovery of LV function
after AMI.
6,7 The use of BMMNC is clinically justiﬁed and ethically
unquestionable because no severe side effects have been reported,
and immunosuppressive therapy is unnecessary. However, most
clinical trials of BMMNC transplantation for AMI patients are
short-term observations with rare reports of long-term follow-up
results. The aim of the present study was to investigate the efﬁcacy
of and LV functional improvement after BMMNC transplantation in
patients with ST-segment elevation myocardial infarction (STEMI)
at up to 4 years follow-up.
Methods
Patient population
Eighty-six STEMI patients with the culprit lesion in the left anterior
descending artery proximal to the two diagonal branches were
enrolled consecutively between July 2003 and March 2004. Patients
were treated by acute PCI successfully within 12 h of the onset of
symptoms. The study protocol was approved by the Ethics Committee
of Fourth Military Medical University. All of the patients gave written,
informed consent. An independent data and safety monitoring board
was informed of adverse events as they occurred.
Inclusion criteria were age between 40 and 65 years old, STEMI
according to the WHO deﬁnition, PCI ,12 h from the onset of symp-
toms, one vessel disease with an open infarct related artery amenable
to cell therapy. General exclusion criteria were previous MI, cardio-
myopathy, atrial ﬁbrillation or ﬂutter, previous heart surgery, severe
valvular heart disease, disease of the haematopoietic system, NYHA
functional class IV heart failure at baseline, severe renal, lung and
liver disease or cancer, signiﬁcant coronary lesion in one or more
major coronary vessels, intracardiac thrombus, and bone marrow
disease.
Study design and baseline evaluation
The study design is shown in Figure 1. A detailed history was recorded.
Creatinine phosphokinase (CK), MB isoenzyme of creatinine kinase
(CK-MB), homocysteine, prothrombin time (PT), thrombin time
(TT), activated partial thromboplastin time (APTT), ﬁbrinogen (FIB),
international normalized ratio (INR), urea nitrogen (UN), creatinine,
routine blood tests, blood cholesterol, blood glucose, and blood
pressure were recorded on the day of admission to the hospital. All
of the patients received medication in accordance with current guide-
lines for the management of patients with STEMI.
8 Patients were ran-
domized to the BMMNC group (n ¼ 41) or saline group (n ¼ 45) as
follows: random numbers between 0 and 1 were generated and a
median value was calculated. Random numbers greater than the
median value were allocated to the BMMNC group. Consecutively
numbered, sealed envelopes were provided by the clinical research
centre of Xijing Hospital. Blood samples were collected. ECG, UCG,
single-photon emission computed tomography analysis (SPECT), and
coronary angiography data were collected. Cumulative major
adverse cardiac events (MACE), including cardiac death, non-fatal
myocardial infarction, and target lesion revascularization, were also
recorded.
Figure 1 Flowchart outlining the study protocol.
Efﬁcacy of BMMNC transplantation for STEMI 1987Bone marrow aspiration and isolation of bone
marrow mononuclear cells
Bone marrow (40 mL) aspiration was conducted 7 days after successful
PCI under local anaesthesia. Density gradient centrifugation was used
to isolate BMMNC. In brief, the bone marrow solution was gently
added onto 10 mL Ficoll (LymphoprepTM, Axis-Shield, Norway,
density 1.073) and centrifuged at 900 g for 30 min at room tempera-
ture. The mononuclear cell layer was harvested and washed three
times before ﬁnal resuspension in 10 mL heparinized saline. The ﬁnal
preparation of the injected cells contained 5+1.2   10
7 mononuclear
cells per millilitre. Cell viability was 96+3.2% and CD34
þ cell fraction
was 1.8+0.6%.
Bone marrow mononuclear cells delivery
After acquiring routine PCI access, an over-the-wire balloon catheter
was advanced to the proximal part of the stented culprit lesion and
inﬂated with four to ﬁve ATM for 1 min to occlude blood ﬂow. At
the same time, 2.5 mL of cell suspension containing 1.25   10
8
BMMNC was injected into the infarct-related coronary artery. This
procedure was repeated four times. The control group did not
undergo bone marrow aspiration and was injected with the same
volume of heparinized saline as the BMMNC groups.
Echocardiographic evaluation of left
ventricular function
Echocardiogram was recorded using a HDI 5000 scanner and an iE 33
scanner (Philips Ultrasound, Washington, DC, USA). Four consecutive
cineloops of four apical views were recorded to analyse LV volumes.
End-systolic volume (ESV), end-diastolic volume (EDV), and left ventri-
cular ejection fraction (LVEF) were calculated using the modiﬁed Simp-
son’s rule according to current guidelines.
9 Wall motion score index
(WMSI) was measured by segment score calculation. Two experienced
ultrasound technicians unaware of treatment allocation processed all
recordings. If a discrepancy between the readings of .5% was
noted, a third blinded observer was called and a consensus achieved.
Quantitative single-photon emission
computed tomography analysis
ECG-gated SPECT imaging was performed as follows at baseline and at
follow-up. Approximately 740–925 MBq (weight-adjusted) of 99 m
Technetium (HTA Co., Ltd, China) was injected at rest. An hour
later, SPECT imaging was initiated, using a 15% window centred over
the 140 keV photopeak. Acquisitions were performed with a two-
detector SPECT (Hawkeye, GE). An Entegra (GE Medical Systems)
processing station was used for processing of all recordings and assess-
ment of LV volumes and infarct size (proportion perfusion defect).
Two experienced nuclear medicine technicians who were blinded to
the treatment allocation processed all recordings. If a discrepancy
between the readings of .5% was noted, a third blinded observer
was called and a consensus achieved.
Quantiﬁcation of coronary artery restenosis
Quantitative coronary angiography (QCA) was evaluated and per-
formed with GE QCA software (GE Innova 2000, Fairﬁeld, CT,
USA). Coronary artery restenosis was deﬁned as more than 50%
loss of luminal diameter within stents at follow-up.
Statistical analysis
Continuous variables that approximated the normal distribution were
expressed as mean+SD or mean+SEM. Comparison between the
BMMNC and the control group was made using repeated-measures
ANOVA. A two-sample t-test was performed for comparison
between groups in a speciﬁc time point. Comparisons between differ-
ent time points during the follow-up periods in the same group were
performed by a paired t-test. Categorical parameters were presented
as proportion or number. Differences between groups were assessed
with the x
2 test or Fisher’s exact test, as appropriate. Two-sided tests
have been used throughout, and P-values less than 0.05 were con-
sidered statistically signiﬁcant. SPSS software package version 14.0
(SPSS, Chicago, IL, USA) was used for data analysis.
Results
Baseline comparison and safety
evaluation of procedure by myocardial
enzyme assay and major adverse
cardiac events
Eighty-six patients were included in the study. There were no
major differences between the two groups in terms of patient
characteristics (Table 1). After intracoronary transplantation of
BMMNC, no statistically signiﬁcant changes were found on CK,
CK-MB, homocysteine, PT, TT, APTT, FIB, INR, UN, creatinine,
routine blood tests, blood cholesterol, blood glucose, blood
pressure or ECG tests (data not shown). One case (2.2%) of
in-stent restenosis in the control group was conﬁrmed by coronary
angiography and was subjected to repeat PCI at 1 year follow-up.
One patient (2.4%) had transient acute heart failure in the
BMMNC group 7 days after cell transplantation and one death
(2.2%) occurred in the control group at 1 year follow-up. No
acute or long-term adverse effects in terms of proarrhythmia,
tumour formation, or intramyocardial calciﬁcation were observed.
Echocardiography evaluation
Left ventricular ejection fraction, WMSI, ESV, and EDV were evalu-
ated by echocardiography (Table 2). Left ventricular ejection fraction
improved in both the BMMNC and the control group during the
follow-up period. The LVEF measured at 6 months (0.484+0.5
vs. 0.457+0.6, P ¼ 0.001), 1 year (0.482+0.7 vs. 0.446+0.6,
P , 0.001), and 4 years (0.505+0.8 vs. 0.464+0.8, P , 0.001)
follow-up was increased signiﬁcantly in the BMMNC group when
compared with the control group (Figure 2B). End-systolic volume
decreased in both the BMMNC and the control group. End-systolic
volume measured at 6 months (60.9+0.8 mL vs. 66.3+1.2 mL,
P , 0.001), 1 year (60.3+1.1 mL vs. 67.0+1.3 mL, P , 0.001),
and 4 years (60.9+1.4 mL vs. 67.2+1.5 mL, P ¼ 0.003) follow-up
was signiﬁcantly decreased in the BMMNC group when compared
with controls (Figure 2C). Wall motion score index was also
decreased in both the BMMNC and the control group. Comparison
between the two groups at 6 months (1.43+0.01 vs. 1.48+0.02,
P ¼ 0.04), 1 year (1.35+0.02 vs. 1.41+0.02, P ¼ 0.02), and 4
years (1.23+0.01 vs. 1.37+0.03, P , 0.001) after cell or standard
therapy demonstrated signiﬁcant differences in WMSI according
to the regional wall motion analysis. No signiﬁcant differences of
EDV were observed between the two groups.
There was a statistically signiﬁcant increase in LVEF between day
7 and 4 years post-MI when comparing the BMMNC group with
F. Cao et al. 1988the control group [mean change 3.5% (CI 95%, 1.4–5.5)%, P ¼
0.001] (Figure 2D and E). Also, the reduction in ESV was signiﬁcantly
greater in the BMMNC group when compared with the control
group over the 4 years study period [mean change 27.6 mL (CI
95%, 211.9 to 23.3 mL), P , 0.001] (Figure 2F and G). There
was no signiﬁcant difference between groups in terms of EDV
change [mean change 25.9 mL (CI 95%, 212.4 to 0.7 mL), P ¼
0.08] (Figure 3A and B). The change in WMSI was also signiﬁcantly
higher in BMMNC group than in control group [mean change
20.16 (CI 95%,20.24 to 20.08), P , 0.001] (Figure 3C and D).
Single-photon emission computed
tomography analysis evaluation
Infarct size, LVEF, ESV, and EDV were evaluated by SPECT. Infarct
size decreased in both the BMMNC and the control groups
(Figure 4A and B), although comparison of infarct size between
the two groups showed no statistical difference at 4 years post-
transplant (0.263+0.007 in BMMNC group vs. 0.281+0.008 in
control group, P ¼ 0.10). (Figure 4C). Changes in infarct size
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Table 1 Characteristics of the patients
Characteristics BMMNC
(n 5 41)
Control
(n 5 45)
P-value
Male (%) 95.1 93.3 1.0
Age (year) 50.7+1.1 51.0+1.0 0.85
Hypertension (%) 48.8 44.4 0.69
Hyperlipidaemia (%) 36.6 35.6 0.92
Diabetes mellitus (%) 24.4 26.7 0.81
Current smoker (%) 61.0 62.2 0.91
UN (mmol/L) 4.2+0.1 4.0+0.1 0.25
Cr (mmol/L) 56.2+2.3 57.8+2.4 0.65
CK peak value (U/L) 3271.1+275.2 3521.9+275.5 0.52
CK-MB peak value
(U/L)
347.6+21.6 375.9+24.8 0.40
Symptom to balloon
time (h)
6.5+0.3 6.8+0.3 0.55
Stent number (total) 47 50 0.29
Angioguard TM
(total)
9 8 0.29
Killip class 0.61
I1 5 1 8
II 22 20
III 4 7
Drug-eluting stents
(%)
85.4 77.8 0.37
Medication
Aspirin (%) 100 100 1.0
Clopidogrel (%) 100 100 1.0
ACE-I/ARB (%) 100 100 1.0
b-Blocker (%) 95.1 95.6 1.0
Statin (%) 100 100 1.0
Values are presented as mean+SEM or number or proportion.
Efﬁcacy of BMMNC transplantation for STEMI 1989Figure 2 Improvement of LVEF and ESV evaluated by echocardiography. LVEF and ESV changes were recorded in a representative patient
from baseline (Day 7) to 4 years after MI. (A) LVEF measured at 6 months, 1 and 4 years’ follow-up was increased signiﬁcantly in the BMMNC
group when compared with the control group (B). ESV in the BMMNC group was decreased signiﬁcantly more than in the control group at
6 months, 1 and 4 years follow-up (*P , 0.05 vs. control) (C). Changes in LVEF and ESV between Day 7 and 4 year were signiﬁcant in the
BMMNC group (D–G). LVEF, left ventricular ejection fraction; ESV, end-systolic volume. Solid circles represent the mean, T bars the standard
error (SE).
F. Cao et al. 1990between day 7 and 4 yr also showed no signiﬁcant difference
between the two groups (29.5+0.9% in BMMNC group vs.
27.1+0.9% in control group, P ¼ 0.06) (Figure 4D). Measure-
ments of LVEF, ESV, and EDV showed similar trends to those
found with echocardiography (data not shown).
Subgroup analysis
Data obtained by echocardiography were subjected to subgroup
analysis. Changes in LVEF between baseline (Day 7) and 4 years
were greater in non-diabetic patients when compared with diabetic
patients [BMMNC: (9.7+5.6)% vs. (7.6+2.8)%, P ¼ 0.26; Control:
(6.7+4.8)% vs. (3.0+2.5)%, P ¼ 0.01] (Figure 5A). Also, patients
aged less than 50 had a greater improvement in LVEF between
baseline and 4 years when compared with patients with age 50 or
more [BMMNC: (10.5+3.3)% vs. (8.0+6.2)%, P ¼ 0.11; Control:
(7.7+4.8)% vs. (4.2+3.8)%, P ¼ 0.01] (Figure 5B). Subgroup
analysis also evaluated patients with hypertension and hyperlipidae-
mia, and the changes in LVEF were not consistent either the
BMMNC and the control group (Figures 5C and D).
Discussion
The efﬁcacy of stem cell transplantation has been demonstrated by
many animal and clinical studies.
7,10 Different cell types have been
proposed for cardiac regeneration, including embryonic stem cells,
skeletal myoblasts, endothelial progenitor cells, and BMMNC.
11–13
In these cell types, BMMNC have gained attention as an easily
accessible, homogeneous cell population for cardiac repair.
Although compelling evidence suggests that intracoronary trans-
plantation of BMMNC can help to enhance the recovery of heart
function after AMI,
6,7,14 the efﬁcacy of BMMNC transplantation
remains controversial. More recently, several meta-analyses evalu-
ating the impact of intracoronary cell therapy on AMI concluded
that stem cell therapy improved LVEF and signiﬁcantly reduced
ESV and myocardial lesion area.
15–17 Of note, the maximal
follow-up period in these studies was 18 months. In the present
study, stem cell therapy improved LVEF by 3.5% when compared
with controls over a 4 years follow-up period. However, the
current cell therapy did not further improve the myocardial viabi-
lity of the infarcted area as assessed by SPECT 4 years after trans-
plantation. These results show that BMMNC transplantation
promotes left ventricle contraction signiﬁcantly and persistently
without potent effects on angiogenesis.
Several mechanisms may underlie LV function improvement in
patients who underwent cell therapy. Reyes et al.
13 have previously
found that BM cells have the potential of integrating into the syn-
cytium of host cardiac myocytes and transdifferentiating into either
myocardial or vascular cells. Induction of cell fusion between
BMMNC and resident myocytes has also been documented in
other studies.
18–21 Although the present study does not provide
Figure 3 Changes of EDV and WMSI between Day 7 and 4 years after the myocardial infarction evaluated by echocardiography. Changes in
EDV between Day 7 and 4 year were not signiﬁcantly different between the two groups (A and B). WMSI improved signiﬁcantly in the BMMNC
group compared with control (C and D). EDV, end-diastolic volume; WMSI, wall motion score index. Solid circles represent the mean, T bars
the standard error (SE).
Efﬁcacy of BMMNC transplantation for STEMI 1991Figure 4 Infarct size evaluated by single-photon emission computed tomography analysis (SPECT). Infarct size decreased in both the bone
marrow mononuclear cells (BMMNC) and the control group (A and B). Comparison of infarct size between the two groups showed no stat-
istical difference (C). Changes in infarct size between Day 7 and 4 years follow-up were not signiﬁcantly different between the two groups (D).
Figure 5 Subgroup analysis. Principle transverse lines represented the mean changes in left ventricular ejection fraction (LVEF) between base-
line and 4 years follow-up. DM, diabetes mellitus; Non-D, non-diabetic patients; HBP, high blood pressure; NBP, normal blood pressure; HL,
hyperlipidaemia; NL, normal lipidaemia.
F. Cao et al. 1992evidence that BMMNC can or cannot differentiate into myocytes
or endothelial cells, the signiﬁcant improvement of LVEF suggests
the possibility of paracrine effects of BMMNC. Numerous studies
have demonstrated that BMMNC are capable of releasing multiple
growth factors including vascular endothelial growth factor,
stromal cell-derived factor-1, insulin-like growth factor, and
platelet-derived growth factor.
22–25 More recent data show that
BMMNC deliver a distinct cocktail of growth factors and cytokines
into infarcted myocardium. These data and the present study indi-
cate that further characterization of the BMMNC secretome may
lead to the identiﬁcation of factors with therapeutic potential
after AMI.
26 These growth factors may intensify ventricular wall
movement, improve LVEF, and delay LV dilation.
In our study, no changes were found in CK, CK-MB, homocys-
teine, PT, TT, APTT, FIB, INR, UN, creatinine, routine blood
tests, blood cholesterol, blood glucose or blood pressure levels,
or ECG data after BMMNC delivery. No acute or long-term
adverse effects, such as proarrhythmias, tumour formation, or
intramyocardial calciﬁcation were observed. These results differed
from those of Villa et al.
27 and Solheim et al.
28 Bone marrow
mononuclear cells transplantation-based clinical trials have been
rife with concerns regarding the safety and side effects of intracor-
onary delivery, including potential cardiac risks such as arrhythmia,
calciﬁcation, inﬂammation, and extracardiac risks such as tumour,
infection, and liver/kidney dysfunction. However, the use of intra-
coronary cell infusion continues to be a popular approach, given
the familiarity of most cardiologists with this well-established pro-
cedure. Our present study demonstrated rare obvious cardiac side
effects and no major extracardiac event, such as tumour or infec-
tion, in both groups during the 4 years follow-up. These results
concur with those of the meta-analysis published by Martin-
Rendon et al.
16 On the basis of our previous studies on stem
cell delivery in small animals,
29 we ﬁnd molecular imaging tech-
niques to be the ideal tools to further assess cellular therapy sys-
tematically in vivo. The results of the present study clearly suggest
the importance of further detailed study in tracking cells and asses-
sing in vivo function in the context of intracoronary, intramyocar-
dial, interstitial retrograde coronary venous, or other delivery
approaches in human clinic trials.
During the follow-up period, one case (2.2%) of in-stent reste-
nosis in the control group was conﬁrmed by coronary angiography
and subjected to repeat PCI at 1 year follow-up. One patient
(2.4%) in the BMMNC group had transient acute heart failure 7
days after cell transplantation and one death (2.2%) occurred in
the control group at 1 year follow-up. When compared with
other studies, the rate of adverse events in this study was relatively
low. This may due to our enrolment of patients around the age of
50 and strict inclusion criteria deﬁning low-risk patients. The high
rate of drug-eluting stent implantation (85.4% in BMMNC group
vs. 77.8% in control group) is another potential reason for the
low rate of adverse events. Although the incidence of MACE
was not statistically different between groups, LV function was
improved signiﬁcantly in the BMMNC group. In order to further
demonstrate the efﬁcacy of BMMNC intervention, exercise
capacity and quality of life should be measured in future studies.
In order to identify patients who beneﬁt most from stem cell
therapy, subgroup analysis was performed. Changes in LVEF
between baseline (Day 7) and 4 years were consistently greater
in non-diabetic patients and with patients aged less than 50 in
both the BMMNC group and the control group. Although the
current population was too small to obtain statistically signiﬁcant
differences, the results indicated that younger patients or patients
without diabetes mellitus may beneﬁt more from stem cell therapy.
In this study, we did not purify isolated BMMNC into a single cell
population such as mesodermal progenitor cells, haematopoietic
progenitor cells, and endothelial progenitor cells, because we are
currently unable to determine which cell type is responsible for
myocardial functional improvement. Bone marrow mononuclear
cells containing different cell types may represent an ideal cell
source for treating different diseases by exerting various protective
effects.
2 A large number of clinical trials have been published
demonstrating the effectiveness of unfractionated BMMNC in
various clinical conditions including AMI, chronic coronary artery
disease, non-ischaemic dilated cardiomyopathy, and chronic ischae-
mic heart failure.
6,7,30–32
The present controlled study indicated that intracoronary trans-
plantation of BMMNC is safe and feasible for STEMI patients who
have undergone PCI and that such treatment can lead to long-term
myocardial functional improvement. The possible mechanisms of
such an outcome include paracrine effects of BMMNC.
However, a detailed explanation delineating the speciﬁc cell type
and molecular mechanism responsible for the observed restora-
tional effect will require more dedicated investigation.
Study limitations
Sample size in the present study was small, so large-scale clinical
trials need to be performed to verify the generalizability of the
present conclusion. Owing to a lack of approved tracking
methods that are safe and applicable in human beings, the survival,
proliferation, and migration of BMMNC could not be visualized
after transplantation. Therefore, the development of ‘molecular
markers’ that can monitor the fate of transplanted BMMNC will
be extremely useful in future studies.
33 In addition, BMMNC
contain a variety of cell types. The detailed mechanism and speciﬁc
cell type responsible for myocardial functional improvement
remains to be clariﬁed.
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